Strata Select™

Personalize immunotherapy with
one simple score

Strata Select is a pan-solid tumor molecular profiling test for patients with advanced cancer that provides treatment selection guidance for immunotherapy and beyond

Confident decision-making

Who will benefit from anti-PD-1/PD-L1 monotherapy?

Strata Select provides you with the information you need to make a critical treatment decision for your patients with advanced cancer – whether to prescribe single agent immunotherapy or combination therapy.

With Strata Select you can:

Find new patient populations likely to respond
Avoid unnecessary combination chemotherapy

Order now Order now

From Our Partners

“Strata Select meets all of my needs for molecular profiling. The fast turnaround time, comprehensive clinically-relevant genomic information presented in an easy-to-read format, expert pathologist assessment of molecular diagnosis, and small sample size requirements ensure I have everything I need – when I need it – to make the best possible treatment decisions for my advanced cancer patients.”

Dr. Adam Forman, MD

Newland Medical Associates

From Our Partners

“Through our research collaboration with Strata Oncology we were able to independently validate the Immunotherapy Response Score (IRS), which fills a critical unmet medical need. Besides TMB and MSI, IRS can independently identify patients who may respond to pembrolizumab across a variety of cancer types (pan-tumor). For IRS High patients — who represent about 20% of all advanced cancer patients — we now have a 1st line single-agent immunotherapy treatment option that can potentially spare patients across many solid tumor types from unnecessary chemotherapy.”

Dr. Sachdev Thomas, MD

Genomic Oncology Lead, Kaiser Permanente Northern California

Get the full picture

Treatment selection guidance
across therapeutic classes

Strata Select combines simultaneous DNA and quantitative RNA sequencing from a single small tumor tissue sample to provide treatment selection guidance for immunotherapy as well as other classes of therapy.

Topics

Immunotherapy Response Score

Genomic Signatures

CGP

Supplemental Insights

doctor-welcoming-a-patient-in-his-office-2022-12-03-22-05-21-utc-1-1

Immunotherapy
Response Score

Immunotherapy Response Score is a pan-solid tumor predictive
diagnostic tool for anti-PD-1/PD-L1 monotherapy benefit.

This innovative biomarker algorithm captures the biology of the
tumor and its microenvironment by combining tumor mutation
burden (TMB) with quantitative expression of PD-L1, PD-1,
ADAM12 and TOP2A.

Create new account Create new account

Genomic Signatures

Strata Select also provides the following genomic signatures:

Tumor mutation burden (TMB)
Microsatellite instability (MSI)

Genomic Signatures

Strata Select also provides the following genomic signatures:

Tumor mutation burden (TMB)
Microsatellite instability (MSI)

doctor-talking-to-other-doctors-at-meeting-2023-04-10-22-01-45-utc-1-2

Comprehensive
Genomic Profiling

Strata Select analyzes DNA and RNA across 437
genes to provide guidance for genomic-alteration
targeted therapies.

DNA analysis

All classes of genomic variants are analyzed:

Single-/multi-nucleotide variants (SNVs)
Short insertions and deletions (indels)
Copy number alterations (CNAs)
Amplifications and deep deletions

RNA analysis

Targeted RNA sequencing enables analysis of 950
individual fusion isoforms involving 59 primary
driver genes.

DNA analysis

All classes of genomic variants are analyzed:

Single-/multi-nucleotide variants (SNVs)
Short insertions and deletions (indels)
Copy number alterations (CNAs)
Amplifications and deep deletions

RNA analysis

Targeted RNA sequencing enables analysis of 950
individual fusion isoforms involving 59 primary
driver genes.

For providers For providers

Comprehensive
Genomic Profiling

Strata Select analyzes DNA and RNA across 437
genes to provide guidance for genomic-alteration
targeted therapies.

Supplemental Insights

Supplemental results based on quantitative RNA sequencing
can be used to help expand treatment selection beyond
immunotherapy and mutation-guided therapies to expression-
based therapeutic classes such as antibody-drug conjugates.

Results may be useful for correlating with treatment response to
approved or investigational therapies, or may confer eligibility for
clinical trials.

Homologous recombination deﬁciency (HRD) results are
provided for patients with ovarian cancer.

Explore our platform